Published on 14 Apr 2024 on Simply Wall St. via Yahoo Finance
Market Sentiment Around Loss-Making Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The US$2.5b market-cap company announced a latest loss of US$185m on 31 December 2023 for its most recent financial year result. Many investors are wondering about the rate at which Rhythm Pharmaceuticals will turn a profit, with the big question being “when will the company breakeven?” In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.
View our latest analysis for Rhythm Pharmaceuticals